JPS5646813A - Antitumorigenic composition - Google Patents

Antitumorigenic composition

Info

Publication number
JPS5646813A
JPS5646813A JP12487979A JP12487979A JPS5646813A JP S5646813 A JPS5646813 A JP S5646813A JP 12487979 A JP12487979 A JP 12487979A JP 12487979 A JP12487979 A JP 12487979A JP S5646813 A JPS5646813 A JP S5646813A
Authority
JP
Japan
Prior art keywords
uracil
antitumorigenic
fluorouracil
formula
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP12487979A
Other languages
Japanese (ja)
Inventor
Setsuo Fujii
Norio Saimi
Setsuo Takeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP12487979A priority Critical patent/JPS5646813A/en
Publication of JPS5646813A publication Critical patent/JPS5646813A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE: An antitumorigenic preparation that contains a 5-fluorouracil and a specific amount of a uracil.
CONSTITUTION: One mole of at least one 5-fluorouracil selected from the compounds of the formula (R1, R2 are H, alkoxymethyl, tetrahydrofuryl, alkylcarbamoyl) and over 20moles of at least one uracil selected from the group consisting of thymine, thymidine, uridine, 2'-deoxyuridine, cytosine, cytidine and 2'-dioxycytidine are included to give a preparation in a form of tablet, capsule or granule for oral administration, or injectable or suppository for parenteral application. The amount of the compound of the formula is suitably 0.5W50mg/kg a day. The combination of a uracil that has no carcinostatic activity develops synergism in carcinostatic effect and increases remarkably the therapeutic index.
COPYRIGHT: (C)1981,JPO&Japio
JP12487979A 1979-09-27 1979-09-27 Antitumorigenic composition Pending JPS5646813A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP12487979A JPS5646813A (en) 1979-09-27 1979-09-27 Antitumorigenic composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12487979A JPS5646813A (en) 1979-09-27 1979-09-27 Antitumorigenic composition

Publications (1)

Publication Number Publication Date
JPS5646813A true JPS5646813A (en) 1981-04-28

Family

ID=14896345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP12487979A Pending JPS5646813A (en) 1979-09-27 1979-09-27 Antitumorigenic composition

Country Status (1)

Country Link
JP (1) JPS5646813A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5335834A (en) * 1976-09-13 1978-04-03 Yoshinobu Watanabe Hydraulic pressure machine for power generation
JPS5392813A (en) * 1976-12-23 1978-08-15 Commercial Decal Inc Heattparting decarcomania and parting paper
JPS53137686A (en) * 1977-05-06 1978-12-01 Matsushita Electric Ind Co Ltd Semiconductor laser unit

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5335834A (en) * 1976-09-13 1978-04-03 Yoshinobu Watanabe Hydraulic pressure machine for power generation
JPS5392813A (en) * 1976-12-23 1978-08-15 Commercial Decal Inc Heattparting decarcomania and parting paper
JPS53137686A (en) * 1977-05-06 1978-12-01 Matsushita Electric Ind Co Ltd Semiconductor laser unit

Similar Documents

Publication Publication Date Title
ES2009168A6 (en) 3'-azido-2',3'-dideoxyuridine anti-retroviral composition.
UA40589C2 (en) method for treating a human suffering from viral infection, pharmaceutical composition, combination of compounds for the preparation of medications and pharmaceutical combination
IL95141A (en) Pharmaceutical compositions comprising 1-(beta-d-arabinofuranosyl)-5-(1-propynyl)uracil or a salt thereof,for use in the treatment of varicella zoster virus
CA2268703A1 (en) Enantiomerically pure .beta.-d-dioxolane nucleosides with selective anti-hepatitis b virus activity
ATE424810T1 (en) A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
HUT51642A (en) Process for producing new 2'-halogenmethylidene, 2'-ethenylidene and 2'-ethinyl cytidine, uridine and guanosine derivatives and pharmaceutical compositions comprising same as active ingredient
IE940696L (en) Antiviral compounds
AU584369B2 (en) Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions
ES8307496A1 (en) Galenic preparation.
HUP0101622A2 (en) Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
IL115747A (en) Polyanionic benzylglycosides of benzene triacid amides and pharmaceutical compositions containing them
JPS5646813A (en) Antitumorigenic composition
De Clercq Antiherpes drugs: promises and pitfalls
JP2688057B2 (en) Anti-adenocarcinoma
IL65787A (en) Antiviral pharmaceutical compositions containing alpha,alpha-dialkyl-adamantylamines
JPS5677226A (en) Antitumorigenic agent
JPS57114512A (en) Antidia beticagent comprising (3-dimethyl-carbamoxy- phenyl)trimethyl ammonium derivative
JPS5718618A (en) Antitumor agent
JPS5564518A (en) Carcinostatic composition
Livingston et al. Cytosine Arabinoside
JPS5780319A (en) Anti-tumor agent having reduced toxicity
JPS5519245A (en) Anti-malignant tumor agent composition
JPS57179118A (en) Antitumor agent
JPS55149213A (en) Remedy of dna for viral disease
JPS5699414A (en) Antitumorigenic agent